Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Operations: 2022-2025

Historic Cash from Operations for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $1.0 million.

  • Axsome Therapeutics' Cash from Operations rose 105.61% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.0 million, marking a year-over-year increase of 23.85%. This contributed to the annual value of -$128.4 million for FY2024, which is 11.49% up from last year.
  • Axsome Therapeutics' Cash from Operations amounted to $1.0 million in Q3 2025, which was up 103.23% from -$32.4 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Cash from Operations peaked at $1.0 million during Q3 2025, and registered a low of -$55.3 million during Q2 2023.
  • Over the past 3 years, Axsome Therapeutics' median Cash from Operations value was -$30.4 million (recorded in 2023), while the average stood at -$31.7 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 818.52% in 2024, then surged by 105.61% in 2025.
  • Axsome Therapeutics' Cash from Operations (Quarterly) stood at -$27.6 million in 2022, then declined by 10.15% to -$30.4 million in 2023, then grew by 13.70% to -$26.2 million in 2024, then skyrocketed by 105.61% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, -$32.4 million for Q2 2025, and -$43.4 million during Q1 2025.